DD259352A5 - Verfahren zur herstellung einer synergistischen kombination von amantadin und selegilin - Google Patents

Verfahren zur herstellung einer synergistischen kombination von amantadin und selegilin Download PDF

Info

Publication number: DD259352A5
Authority: DD; German Democratic Republic
Prior art keywords: amantadine; selegiline; weight; parts; salts
Prior art date: 1986-04-16

Application number

DD87301815A

Other languages

German (de)

English (en)

Inventor

Dirk Reischig

Helmut Hettche

Wolfgang Brade

Original Assignee

��@��k��

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-04-16

Filing date

1987-04-14

Publication date

1988-08-24

1987-04-14 Application filed by ��@��k�� filed Critical ��@��k��

1988-08-24 Publication of DD259352A5 publication Critical patent/DD259352A5/de

Links

DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 title claims abstract description 56
229960003805 amantadine Drugs 0.000 title claims abstract description 55
229960003946 selegiline Drugs 0.000 title claims abstract description 40
MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 title claims abstract description 40
238000004519 manufacturing process Methods 0.000 title claims abstract description 8
239000011885 synergistic combination Substances 0.000 title claims abstract description 7
238000002360 preparation method Methods 0.000 claims abstract description 14
239000012050 conventional carrier Substances 0.000 claims abstract description 3
239000000203 mixture Substances 0.000 claims description 18
150000003839 salts Chemical class 0.000 claims description 10
239000000243 solution Substances 0.000 claims description 10
239000004480 active ingredient Substances 0.000 claims description 9
229920002472 Starch Polymers 0.000 claims description 7
239000002253 acid Substances 0.000 claims description 7
239000002775 capsule Substances 0.000 claims description 7
239000000546 pharmaceutical excipient Substances 0.000 claims description 7
239000008107 starch Substances 0.000 claims description 7
235000019698 starch Nutrition 0.000 claims description 7
150000007513 acids Chemical class 0.000 claims description 6
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 6
108010010803 Gelatin Proteins 0.000 claims description 5
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 5
235000010980 cellulose Nutrition 0.000 claims description 5
229920002678 cellulose Polymers 0.000 claims description 5
239000001913 cellulose Substances 0.000 claims description 5
229920000159 gelatin Polymers 0.000 claims description 5
239000008273 gelatin Substances 0.000 claims description 5
235000019322 gelatine Nutrition 0.000 claims description 5
235000011852 gelatine desserts Nutrition 0.000 claims description 5
239000002904 solvent Substances 0.000 claims description 4
FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 3
235000019700 dicalcium phosphate Nutrition 0.000 claims description 3
239000003085 diluting agent Substances 0.000 claims description 3
239000008187 granular material Substances 0.000 claims description 3
229940116364 hard fat Drugs 0.000 claims description 3
235000019359 magnesium stearate Nutrition 0.000 claims description 3
229920001577 copolymer Polymers 0.000 claims description 2
239000007788 liquid Substances 0.000 claims description 2
239000000377 silicon dioxide Substances 0.000 claims description 2
JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims 1
229920000881 Modified starch Polymers 0.000 claims 1
239000004368 Modified starch Substances 0.000 claims 1
239000012895 dilution Substances 0.000 claims 1
238000010790 dilution Methods 0.000 claims 1
239000006185 dispersion Substances 0.000 claims 1
235000019426 modified starch Nutrition 0.000 claims 1
229940083466 soybean lecithin Drugs 0.000 claims 1
230000000694 effects Effects 0.000 abstract description 14
239000000126 substance Substances 0.000 abstract description 12
239000003814 drug Substances 0.000 abstract description 7
238000000034 method Methods 0.000 abstract description 5
208000027089 Parkinsonian disease Diseases 0.000 abstract description 3
206010034010 Parkinsonism Diseases 0.000 abstract description 3
230000008719 thickening Effects 0.000 abstract 1
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 14
238000009472 formulation Methods 0.000 description 11
CFFZDZCDUFSOFZ-UHFFFAOYSA-N 3,4-Dihydroxy-phenylacetic acid Chemical compound OC(=O)CC1=CC=C(O)C(O)=C1 CFFZDZCDUFSOFZ-UHFFFAOYSA-N 0.000 description 10
QRMZSPFSDQBLIX-UHFFFAOYSA-N homovanillic acid Chemical compound COC1=CC(CC(O)=O)=CC=C1O QRMZSPFSDQBLIX-UHFFFAOYSA-N 0.000 description 10
-1 saturated aliphatic alcohols Chemical class 0.000 description 9
WOLHOYHSEKDWQH-UHFFFAOYSA-N amantadine hydrochloride Chemical compound [Cl-].C1C(C2)CC3CC2CC1([NH3+])C3 WOLHOYHSEKDWQH-UHFFFAOYSA-N 0.000 description 7
229960001280 amantadine hydrochloride Drugs 0.000 description 7
229960003638 dopamine Drugs 0.000 description 7
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
239000013543 active substance Substances 0.000 description 6
IYETZZCWLLUHIJ-UHFFFAOYSA-N methyl-(1-phenylpropan-2-yl)-prop-2-ynylazanium;chloride Chemical compound Cl.C#CCN(C)C(C)CC1=CC=CC=C1 IYETZZCWLLUHIJ-UHFFFAOYSA-N 0.000 description 6
229960003678 selegiline hydrochloride Drugs 0.000 description 6
230000002195 synergetic effect Effects 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
208000018737 Parkinson disease Diseases 0.000 description 5
239000000939 antiparkinson agent Substances 0.000 description 5
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 4
230000000648 anti-parkinson Effects 0.000 description 4
125000004432 carbon atom Chemical group C* 0.000 description 4
235000014113 dietary fatty acids Nutrition 0.000 description 4
229940079593 drug Drugs 0.000 description 4
150000002148 esters Chemical class 0.000 description 4
239000000194 fatty acid Substances 0.000 description 4
229930195729 fatty acid Natural products 0.000 description 4
239000010695 polyglycol Substances 0.000 description 4
229920000151 polyglycol Polymers 0.000 description 4
229940032147 starch Drugs 0.000 description 4
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
239000003995 emulsifying agent Substances 0.000 description 3
LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 3
238000004128 high performance liquid chromatography Methods 0.000 description 3
235000010445 lecithin Nutrition 0.000 description 3
239000000787 lecithin Substances 0.000 description 3
229940067606 lecithin Drugs 0.000 description 3
239000003921 oil Substances 0.000 description 3
235000019198 oils Nutrition 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
229930003799 tocopherol Natural products 0.000 description 3
239000011732 tocopherol Substances 0.000 description 3
235000019149 tocopherols Nutrition 0.000 description 3
QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 3
PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
229920002261 Corn starch Polymers 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
239000005642 Oleic acid Substances 0.000 description 2
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
239000003963 antioxidant agent Substances 0.000 description 2
235000006708 antioxidants Nutrition 0.000 description 2
235000010323 ascorbic acid Nutrition 0.000 description 2
239000011668 ascorbic acid Substances 0.000 description 2
229960005070 ascorbic acid Drugs 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical class [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
239000000969 carrier Substances 0.000 description 2
239000004359 castor oil Substances 0.000 description 2
235000019438 castor oil Nutrition 0.000 description 2
229920003086 cellulose ether Polymers 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
235000005687 corn oil Nutrition 0.000 description 2
239000002285 corn oil Substances 0.000 description 2
239000008120 corn starch Substances 0.000 description 2
239000002537 cosmetic Substances 0.000 description 2
235000012343 cottonseed oil Nutrition 0.000 description 2
239000002385 cottonseed oil Substances 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
150000004665 fatty acids Chemical class 0.000 description 2
150000002191 fatty alcohols Chemical class 0.000 description 2
235000004515 gallic acid Nutrition 0.000 description 2
229940074391 gallic acid Drugs 0.000 description 2
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
238000005469 granulation Methods 0.000 description 2
230000003179 granulation Effects 0.000 description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
238000002156 mixing Methods 0.000 description 2
210000001577 neostriatum Anatomy 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
239000004006 olive oil Substances 0.000 description 2
235000008390 olive oil Nutrition 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
239000000047 product Substances 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
235000003441 saturated fatty acids Nutrition 0.000 description 2
239000008159 sesame oil Substances 0.000 description 2
235000011803 sesame oil Nutrition 0.000 description 2
235000012239 silicon dioxide Nutrition 0.000 description 2
150000003626 triacylglycerols Chemical class 0.000 description 2
239000008215 water for injection Substances 0.000 description 2
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
MFJCORKPUUOBMV-UHFFFAOYSA-N 1,1,2-trichloro-2-methylpropan-1-ol Chemical compound CC(C)(Cl)C(O)(Cl)Cl MFJCORKPUUOBMV-UHFFFAOYSA-N 0.000 description 1
ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Polymers FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
239000004255 Butylated hydroxyanisole Substances 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
241000288673 Chiroptera Species 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
229920000858 Cyclodextrin Polymers 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
241000282412 Homo Species 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
241000195947 Lycopodium Species 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
229940086616 Monoamine oxidase B inhibitor Drugs 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
206010039792 Seborrhoea Diseases 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
239000003568 Sodium, potassium and calcium salts of fatty acids Substances 0.000 description 1
239000004147 Sorbitan trioleate Substances 0.000 description 1
PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
206010044565 Tremor Diseases 0.000 description 1
239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
210000000683 abdominal cavity Anatomy 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000007059 acute toxicity Effects 0.000 description 1
231100000403 acute toxicity Toxicity 0.000 description 1
238000005273 aeration Methods 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
125000005907 alkyl ester group Chemical group 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
230000001430 anti-depressive effect Effects 0.000 description 1
229940035678 anti-parkinson drug Drugs 0.000 description 1
230000002421 anti-septic effect Effects 0.000 description 1
239000000935 antidepressant agent Substances 0.000 description 1
229940005513 antidepressants Drugs 0.000 description 1
229940125688 antiparkinson agent Drugs 0.000 description 1
239000002830 appetite depressant Substances 0.000 description 1
210000004227 basal ganglia Anatomy 0.000 description 1
UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
229960001950 benzethonium chloride Drugs 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
229960002903 benzyl benzoate Drugs 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
229940043253 butylated hydroxyanisole Drugs 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
235000013969 calcium salts of fatty acid Nutrition 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
238000000576 coating method Methods 0.000 description 1
235000012716 cod liver oil Nutrition 0.000 description 1
239000003026 cod liver oil Substances 0.000 description 1
239000003086 colorant Substances 0.000 description 1
230000009918 complex formation Effects 0.000 description 1
239000007859 condensation product Substances 0.000 description 1
229930003836 cresol Natural products 0.000 description 1
229940097362 cyclodextrins Drugs 0.000 description 1
235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
150000004862 dioxolanes Chemical class 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
125000005912 ethyl carbonate group Chemical class 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
230000008921 facial expression Effects 0.000 description 1
239000003925 fat Substances 0.000 description 1
238000011049 filling Methods 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
229910021485 fumed silica Inorganic materials 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
229940074076 glycerol formal Drugs 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
229940093915 gynecological organic acid Drugs 0.000 description 1
210000002837 heart atrium Anatomy 0.000 description 1
229910001385 heavy metal Inorganic materials 0.000 description 1
239000008240 homogeneous mixture Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
SXQFCVDSOLSHOQ-UHFFFAOYSA-N lactamide Chemical class CC(O)C(N)=O SXQFCVDSOLSHOQ-UHFFFAOYSA-N 0.000 description 1
150000003893 lactate salts Chemical class 0.000 description 1
239000008101 lactose Substances 0.000 description 1
229960001375 lactose Drugs 0.000 description 1
239000006210 lotion Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
235000010933 magnesium salts of fatty acid Nutrition 0.000 description 1
239000001778 magnesium salts of fatty acids Substances 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
HCZKYJDFEPMADG-TXEJJXNPSA-N masoprocol Chemical compound C([C@H](C)[C@H](C)CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-TXEJJXNPSA-N 0.000 description 1
239000012528 membrane Substances 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
YLGXILFCIXHCMC-JHGZEJCSSA-N methyl cellulose Chemical compound COC1C(OC)C(OC)C(COC)O[C@H]1O[C@H]1C(OC)C(OC)C(OC)OC1COC YLGXILFCIXHCMC-JHGZEJCSSA-N 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
201000003631 narcolepsy Diseases 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
235000014593 oils and fats Nutrition 0.000 description 1
239000002674 ointment Substances 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000006201 parenteral dosage form Substances 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
239000001814 pectin Substances 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
229960000292 pectin Drugs 0.000 description 1
WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
229960004838 phosphoric acid Drugs 0.000 description 1
235000011007 phosphoric acid Nutrition 0.000 description 1
229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
229920001296 polysiloxane Polymers 0.000 description 1
239000011148 porous material Substances 0.000 description 1
150000003138 primary alcohols Chemical class 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
150000004671 saturated fatty acids Chemical class 0.000 description 1
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
239000002356 single layer Substances 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
235000010234 sodium benzoate Nutrition 0.000 description 1
239000004299 sodium benzoate Substances 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
229940001584 sodium metabisulfite Drugs 0.000 description 1
235000010262 sodium metabisulphite Nutrition 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
235000019337 sorbitan trioleate Nutrition 0.000 description 1
229960000391 sorbitan trioleate Drugs 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
239000008347 soybean phospholipid Substances 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
238000003756 stirring Methods 0.000 description 1
229960004793 sucrose Drugs 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000005846 sugar alcohols Polymers 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
235000020238 sunflower seed Nutrition 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
238000012360 testing method Methods 0.000 description 1
BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
150000004670 unsaturated fatty acids Chemical class 0.000 description 1
235000021122 unsaturated fatty acids Nutrition 0.000 description 1
210000001364 upper extremity Anatomy 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
239000010497 wheat germ oil Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/315—Zinc compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Neurology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Luminescent Compositions (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Plural Heterocyclic Compounds (AREA)
Saccharide Compounds (AREA)
Medicinal Preparation (AREA)

DD87301815A 1986-04-16 1987-04-14 Verfahren zur herstellung einer synergistischen kombination von amantadin und selegilin DD259352A5 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE3612702		1986-04-16

Publications (1)

Publication Number	Publication Date
DD259352A5 true DD259352A5 (de)	1988-08-24

Family

ID=6298731

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DD87301815A DD259352A5 (de)	1986-04-16	1987-04-14	Verfahren zur herstellung einer synergistischen kombination von amantadin und selegilin

Country Status (19)

Country	Link
US (1)	US4812481A (da)
EP (1)	EP0241809B1 (da)
JP (1)	JPS62249923A (da)
AT (1)	ATE55245T1 (da)
AU (1)	AU598533B2 (da)
CA (1)	CA1298200C (da)
DD (1)	DD259352A5 (da)
DE (1)	DE3764144D1 (da)
DK (1)	DK168514B1 (da)
ES (1)	ES2029805T3 (da)
FI (1)	FI871668A7 (da)
GR (1)	GR3000707T3 (da)
HU (1)	HU197840B (da)
IE (1)	IE60245B1 (da)
IL (1)	IL82216A0 (da)
NO (1)	NO871581L (da)
PL (1)	PL265152A1 (da)
PT (1)	PT84684B (da)
ZA (1)	ZA872690B (da)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6150328A (en)	1986-07-01	2000-11-21	Genetics Institute, Inc.	BMP products
US4861800A (en) *	1987-08-18	1989-08-29	Buyske Donald A	Method for administering the drug deprenyl so as to minimize the danger of side effects
GB8807504D0 (en) *	1988-03-29	1988-05-05	Sandoz Ltd	Improvements in/relating to organic compounds
HU208484B (en) *	1988-08-17	1993-11-29	Chinoin Gyogyszer Es Vegyeszet	Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia
AU654143B2 (en) *	1990-06-25	1994-10-27	Du Pont Merck Pharmaceutical Company, The	Amantadine hydrochloride suspension with enhanced dissolution characteristics for use in soft gelatin capsules
US5175002A (en) *	1991-10-02	1992-12-29	Du Pont Merck Pharmaceutical Company	Amantadine hydrochloride syspension with enhanced dissolution characteristics for use in soft gelatin capsules
WO1993009229A1 (en)	1991-11-04	1993-05-13	Genetics Institute, Inc.	Recombinant bone morphogenetic protein heterodimers, compositions and methods of use
HUT63579A (en) *	1991-12-20	1993-09-28	Chinoin Gyogyszer Es Vegyeszet	Process for producing double-phase pharmaceutical compositions suitable for treating diseases occurring during neurodegenerative processes
US5817336A (en) *	1993-04-02	1998-10-06	Orion-Yhtyma Oy	Composition containing selegiline
US6291206B1 (en)	1993-09-17	2001-09-18	Genetics Institute, Inc.	BMP receptor proteins
AU689184B2 (en)	1993-12-07	1998-03-26	Genetics Institute, Llc	BMP-12, BMP-13 and tendon-inducing compositions thereof
US5484608A (en) *	1994-03-28	1996-01-16	Pharmavene, Inc.	Sustained-release drug delivery system
GB9426079D0 (en) *	1994-12-23	1995-02-22	Orion Yhtymae Oy	A gelatine capsule
US6033682A (en)	1995-01-13	2000-03-07	Somerset Pharmaceuticals, Inc.	S(+) desmethylselegiline and its use in therapeutic methods and pharmaceutical compositions
US6348208B1 (en) *	1995-01-13	2002-02-19	Somerset Pharmaceuticals, Inc.	Methods and pharmaceutical compositions employing desmethylselegiline
US6319954B1 (en)	1995-01-13	2001-11-20	Somerset Pharmaceuticals, Inc.	S-(+)-desmethylselegiline and its use in the therapeutic methods and pharmaceutical compositions
US6299901B1 (en)	1995-01-13	2001-10-09	Somerset Pharmaceuticals, Inc.	Methods and pharmaceutical compositions employing desmethylselegiline
DE19533772C1 (de) *	1995-09-12	1998-01-02	Hexal Ag	Tacrin/Selegilin-Pflaster
JPH11504944A (ja) *	1995-11-06	1999-05-11	サマーセット・ファーマシューティカルズ・インコーポレイテッド	セレギリンの舌下およびバッカル投与
DE19716905C1 (de) *	1997-04-22	1998-08-27	Iip Inst Fuer Ind Pharmazie Fo	Stabile, wäßrige Lösung auf der Grundlage von Selegilin und Vorrichtung zu ihrer Verabreichung
GB9715082D0 (en) *	1997-07-17	1997-09-24	Scherer Ltd R P	Treatment of attention deficit hyperactivity disorder and narcolepsy
DK1063981T3 (da) *	1998-03-16	2002-10-14	Somerset Pharmaceuticals Inc	Anvendelse af selegilin eller desmethylselegilin til behandling af sår, brandsår og dermatologiske skader
US6727224B1 (en)	1999-02-01	2004-04-27	Genetics Institute, Llc.	Methods and compositions for healing and repair of articular cartilage
AU1359801A (en) *	1999-11-05	2001-06-06	Vela Pharmaceuticals Inc.	Methods and compositions for treating reward deficiency syndrome
US20040122090A1 (en) *	2001-12-07	2004-06-24	Lipton Stuart A.	Methods for treating neuropsychiatric disorders with nmda receptor antagonists
US7226587B2 (en)	2001-06-01	2007-06-05	Wyeth	Compositions and methods for systemic administration of sequences encoding bone morphogenetic proteins
TWI267378B (en)	2001-06-08	2006-12-01	Wyeth Corp	Calcium phosphate delivery vehicles for osteoinductive proteins
CN1891213A (zh) *	2002-03-04	2007-01-10	萨默塞特医药公司	应用去甲司来吉兰预防和治疗周围神经病的方法
JP2006524708A (ja) *	2003-04-25	2006-11-02	インディヴァスファーマシューティカルズ，インコーポレーテッド	塩化トロスピウムの投与により連続睡眠を促進するための方法
DE10338174A1 (de)	2003-08-20	2005-03-24	Lts Lohmann Therapie-Systeme Ag	Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit
JP5392981B2 (ja)	2003-09-12	2014-01-22	ワイス・エルエルシー	骨形成蛋白の送達のための注入可能なリン酸カルシウム固体ロッドおよびペースト
EP1715843A1 (en) *	2004-01-29	2006-11-02	Neuromolecular Inc.	Combination of a nmda receptor antagonist and a mao-inhibitor or a gadph-inhibitor for the treatment of central nervous system-related conditions
WO2005079756A2 (en) *	2004-02-13	2005-09-01	Neuromolecular, Inc.	Combination of a nmda receptor antagonist and an anti-depressive drug mao-inhibitor or a gadph-inhibitor for the treatment of psychiatric conditions
US7619007B2 (en) *	2004-11-23	2009-11-17	Adamas Pharmaceuticals, Inc.	Method and composition for administering an NMDA receptor antagonist to a subject
EP2623099A1 (en)	2004-11-24	2013-08-07	Neuromolecular Pharmaceuticals, Inc	Composition and method for treating neurological disease
US20060264478A1 (en) *	2005-02-22	2006-11-23	Northwestern University	Methods and compositions for modulating calcium channels
ES2564187T3 (es)	2005-04-05	2016-03-18	Yale University	Agentes de modulación de glutamato en el tratamiento de trastornos mentales
ATE481096T1 (de)	2005-04-06	2010-10-15	Adamas Pharmaceuticals Inc	Verfahren und zusammensetzungen zur behandlung von zns-erkrankungen
US8969417B2 (en) †	2008-06-06	2015-03-03	Pharmatwob Ltd.	Pharmaceutical compositions for treatment of Parkinsons disease
CA2994873A1 (en)	2009-12-02	2011-06-09	Adamas Pharma, Llc	Amantadine compositions and methods of use
US10154971B2 (en)	2013-06-17	2018-12-18	Adamas Pharma, Llc	Methods of administering amantadine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE314077C (da) *
AT314077B (de) *	1972-01-07	1974-03-25	Hurka Wilhelm	Verfahren zur Herstellung eines neuen, gegen den Parkinsonismus wirksamen Kombinationspräparates
HU193662B (en) *	1983-12-20	1987-11-30	Chinoin Gyogyszer Es Vegyeszet	Process for producing synergetic pharmaceutical composition of antidepressive aktivity

1987
- 1987-04-01 DE DE8787104818T patent/DE3764144D1/de not_active Expired - Lifetime
- 1987-04-01 AT AT87104818T patent/ATE55245T1/de not_active IP Right Cessation
- 1987-04-01 EP EP87104818A patent/EP0241809B1/de not_active Expired - Lifetime
- 1987-04-01 ES ES198787104818T patent/ES2029805T3/es not_active Expired - Lifetime
- 1987-04-13 JP JP62088986A patent/JPS62249923A/ja active Pending
- 1987-04-14 DD DD87301815A patent/DD259352A5/de unknown
- 1987-04-14 ZA ZA872690A patent/ZA872690B/xx unknown
- 1987-04-14 NO NO871581A patent/NO871581L/no unknown
- 1987-04-14 IE IE97387A patent/IE60245B1/en not_active IP Right Cessation
- 1987-04-14 PL PL1987265152A patent/PL265152A1/xx unknown
- 1987-04-15 DK DK197787A patent/DK168514B1/da not_active IP Right Cessation
- 1987-04-15 PT PT84684A patent/PT84684B/pt not_active IP Right Cessation
- 1987-04-15 FI FI871668A patent/FI871668A7/fi not_active Application Discontinuation
- 1987-04-15 AU AU71541/87A patent/AU598533B2/en not_active Ceased
- 1987-04-15 US US07/038,566 patent/US4812481A/en not_active Expired - Fee Related
- 1987-04-15 CA CA000534793A patent/CA1298200C/en not_active Expired - Lifetime
- 1987-04-16 IL IL82216A patent/IL82216A0/xx unknown
- 1987-04-16 HU HU871687A patent/HU197840B/hu not_active IP Right Cessation
1990
- 1990-08-09 GR GR90400531T patent/GR3000707T3/el unknown

Also Published As

Publication number	Publication date
IL82216A0 (en)	1987-10-30
AU598533B2 (en)	1990-06-28
IE60245B1 (en)	1994-06-15
FI871668L (fi)	1987-10-17
NO871581D0 (no)	1987-04-14
ES2029805T3 (es)	1992-10-01
FI871668A7 (fi)	1987-10-17
EP0241809B1 (de)	1990-08-08
DK168514B1 (da)	1994-04-11
PT84684A (de)	1987-05-01
ZA872690B (en)	1988-03-30
EP0241809A1 (de)	1987-10-21
DK197787A (da)	1987-10-17
GR3000707T3 (en)	1991-10-10
JPS62249923A (ja)	1987-10-30
DK197787D0 (da)	1987-04-15
NO871581L (no)	1987-10-19
DE3764144D1 (de)	1990-09-13
HU197840B (en)	1989-06-28
ATE55245T1 (de)	1990-08-15
CA1298200C (en)	1992-03-31
PL265152A1 (en)	1988-07-07
AU7154187A (en)	1987-10-29
US4812481A (en)	1989-03-14
PT84684B (pt)	1989-12-29
FI871668A0 (fi)	1987-04-15
HUT43789A (en)	1987-12-28
IE870973L (en)	1987-10-16

Publication	Publication Date	Title
EP0241809B1 (de)	1990-08-08	Synergistische Kombination von Amantadin und Selegilin
EP0467164B1 (de)	1996-01-31	Flupirtin in Kombination mit Antiparkinsonika zur Bekämpfung von Muskelverspannungen
DE3586545T2 (de)	1993-03-04	Erhoehte schmerzlosigkeit bewirkende pharmazeutische zusammensetzungen.
DE69435095T2 (de)	2009-07-02	Neue Behandlungsmethoden durch Verwendung von Phenethylaminderivaten
DE60035870T2 (de)	2008-05-08	Kombinationstherapie zur gewichtsreduzierung und fettleibigkeitsbehandlung
DE69730688T2 (de)	2005-09-22	Oral anzuwendende arzneizubereitung
EP0427247A2 (de)	1991-05-15	Arzneimittel enthaltend als Wirkstoff R-alpha-Liponsäure oder S-alpha-Liponsäure
EP0277352B1 (de)	1991-10-16	Synergistische Kombination von Azelastin und Theophyllin oder Azelastin und Beta-Mimetika
EP1051170A1 (de)	2000-11-15	Verwendung von substituierten aminomethyl-chromanen zur verhinderung der neuronalen degeneration und zur förderung der neuronalen regeneration
DE69907509T2 (de)	2004-04-08	Pphospholipidkomplexe von proanthocyanidin a2 als antiatherosklerotische mittel
DE69828390T2 (de)	2005-06-02	Antikrebs-zusammensetzung
DE4029747C2 (de)	2003-10-02	Verwendung von Hexadecylphosphocholin zur Behandlung von Psoriasis-Erkrankungen
DE69814089T2 (de)	2004-02-19	Verwendung von einem draflazin analog zur schmerzbehandlung
DE69630073T2 (de)	2004-06-17	(-)Hydroxycitrat enthaltende Verbindungen mit neuen therapeutischen Wirkungen
DD242349A5 (de)	1987-01-28	Verfahren zur herstellung einer synergistischen kombination von flupirtin und 4-acetamido-phenol
DE3710966A1 (de)	1987-12-03	Synergistische kombination von amantadin und selegilin
DE10163421A1 (de)	2003-07-31	Verwendung von (+)-(1S,2S)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)phenol als Antiemetikum
DE2633891A1 (de)	1977-02-17	Neues salz der alpha-methylbenzoyl- 5-thiophen-2-essigsaeure, verfahren zu dessen herstellung und pharmazeutische zusammensetzungen
DE2462711C2 (de)	1979-11-08	Verwendung von 2,6-cis-Diphenylhexamethylcyclotetrasiloxan
DE3406837A1 (de)	1984-08-30	Arteriosklerose-arzneimittel und -prophylaktikum
DE3116232A1 (de)	1982-03-04	Nonaprenylamin-derivate und sie enthaltende pharmazeutische mittel
DE2810051A1 (de)	1978-09-28	Zubereitung fuer die behandlung von asthma
DE2618500A1 (de)	1976-11-18	Pharmazeutische zubereitung fuer die behandlung von bluthochdruck
DE69524949T2 (de)	2002-06-20	Eisen-Chelatierformulierung und Verfahren zu ihrer Herstellung
CN114096314A (zh)	2022-02-25	痴呆症的治疗和预防药